Zobrazeno 1 - 9
of 9
pro vyhledávání: '"T. B. Andersson"'
Autor:
M, Keisu, T B, Andersson
Publikováno v:
Handbook of experimental pharmacology. (196)
Ximelagatran was the first orally available direct thrombin inhibitor under clinical development that also reached the market. Ximelagatran was tested in an extensive clinical programme. Short-term use (12 days) in humans including the phase III clin
Autor:
M Ulvestad, I. B. Skottheim, G Signe Jakobsen, S Bremer, E Molden, A Åsberg, Jøran Hjelmesaeth, T. B. Andersson, R Sandbu, H Christensen
Publikováno v:
Clinical Pharmacology & Therapeutics. 97:428-428
Autor:
M D, Sadar, T B, Andersson
Publikováno v:
In vitro cellulardevelopmental biology. Animal. 37(3)
Primary cultures of fish hepatocytes have been used as a convenient model for studies on cytochrome expression. Here we have further examined the regulation of CYP enzymes in this model. A transient increase in CYP1A1 messenger ribonucleic acid (mRNA
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 28(8)
This study demonstrates the stereoselective metabolism of the optical isomers of omeprazole in human liver microsomes. The intrinsic clearance (CL(int)) of the formation of the hydroxy metabolite from S-omeprazole was 10-fold lower than that from R-o
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 28(1)
H 259/31 is a substituted benzimidazole developed as a structural analog of omeprazole. Metabolites of H 259/31 formed in human liver microsomes were identified by using the synthetic reference compounds and liquid chromatography/mass spectrometry. T
Autor:
C M, Masimirembwa, C, Otter, M, Berg, M, Jönsson, B, Leidvik, E, Jonsson, T, Johansson, A, Bäckman, A, Edlund, T B, Andersson
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 27(10)
Drug metabolism studies in the early phases of drug discovery and development will improve the selection of new chemical entities that will be successful in clinical trials. To meet the expanding demands for these studies on the numerous chemicals ge
Autor:
S, Döppenschmitt, P, Langguth, C G, Regårdh, T B, Andersson, C, Hilgendorf, H, Spahn-Langguth
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 288(1)
Interaction with the exsorptive transporter P-glycoprotein (P-gp) is a possible source of peculiarities in drug pharmacokinetics, including dose-dependent absorption, drug-drug interactions, intestinal secretion, and limited permeability of the blood
Publikováno v:
The Journal of biological chemistry. 271(30)
In mammals, phenobarbital (PB) is an in vivo inducer of the cytochrome P4502B (CYP2B) family, whereas in teleosts PB induction of cytochrome P450 is unclear. We show that teleost cytochrome P4502K1 (CYP2K1) protein levels and 7-pentoxyresorufin-O-dee
Autor:
Hildegard Spahn-Langguth, T B Andersson, Peter Langguth, Sibylle Neuhoff, C G Regårdh, C Dressler
Publikováno v:
Europe PubMed Central
Objectives The multidrug transporter P-glycoprotein (P-gp) appears to play a significant role in drug absorption and disposition. Hence, it is of interest to evaluate structure-affinity relationships for the purpose of making predictions. Methods The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d3fda7a8ed41ab6c8220cf0d8602e3
http://europepmc.org/abstract/med/10783826
http://europepmc.org/abstract/med/10783826